Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Grifols Sa (NASDAQ: GRFS).

Full DD Report for GRFS

You must become a subscriber to view this report.


Recent News from (NASDAQ: GRFS)

36 'Safer' Dividend Healthcare WallStars For September
Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.1% to 21.82% Gains To September 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for...
Source: SeekingAlpha
Date: September, 12 2018 22:35
Aceto 72% Target Net Gain Tops WallStar Healthcare Equities For September
Actionable Conclusions (1-10): Analysts Projected 13.4% To 72.2% Net Gains For Top Ten Healthcare WallStars By September 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices....
Source: SeekingAlpha
Date: September, 12 2018 14:40
Principia Biopharma Readies $75 Million IPO Plans
Quick Take Principia Biopharma ( PRNB ) intends to raise $75.0 million from the sale of its common stock, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for pemphigus, purpura and other diseases. PRNB is a mid-stage biopharma...
Source: SeekingAlpha
Date: September, 06 2018 10:42
Principia Biopharma Begins U.S. IPO Effort
Quick Take Principia Biopharma ( PRNB ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The clinical-stage biopharmaceutical firm researches and develops pharmaceutical treatments for inflammatory and autoimmune diseases. ...
Source: SeekingAlpha
Date: August, 22 2018 11:49
Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins
EMERYVILLE, Calif. , Aug. 16, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with a history of more than 75 years of improving people's health and well-being and a leader in the development of innovative diagnostic solutions, recentl...
Source: PR Newswire
Date: August, 16 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1420.5519.9720.6219.961,528,269
2017-02-0317.3017.4217.4317.26511,664
2017-02-0217.1617.1517.206717.05730,693
2017-02-0117.0417.2117.2216.891,474,169
2017-01-3117.0917.0017.1116.94940,839

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1443,052108,10139.8257Short
2018-12-1337,435290,08512.9048Cover
2018-12-1277,677441,95517.5758Cover
2018-12-1163,453332,05719.1091Cover
2018-12-1052,108192,15127.1183Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GRFS.


About Grifols Sa (NASDAQ: GRFS)

Logo for Grifols Sa (NASDAQ: GRFS)

Not available

 

Contact Information

 

 

Current Management

  • Victor Grifols Roura / CEO
  • Victor Grifols Roura / Chairman

Current Share Structure

  • Authorized: 5,942,192,750 - 05/16/2018

 



Daily Technical Chart for (NASDAQ: GRFS)

Daily Technical Chart for (NASDAQ: GRFS)


Stay tuned for daily updates and more on (NASDAQ: GRFS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GRFS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GRFS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GRFS and does not buy, sell, or trade any shares of GRFS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/